Albireo Pharma Gestione

Gestione criteri di controllo 2/4

Albireo Pharma Il CEO è Ron Cooper, nominato in Jul2015, e ha un mandato di 7.67 anni. la retribuzione annua totale è $ 6.04M, composta da 9.8% di stipendio e 90.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di MX$ 26.49M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 5.5 anni.

Informazioni chiave

Ron Cooper

Amministratore delegato

US$6.0m

Compenso totale

Percentuale dello stipendio del CEO	9.8%
Mandato del CEO	7.7yrs
Proprietà del CEO	0.2%
Durata media del management	4.2yrs
Durata media del Consiglio di amministrazione	5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ron Cooper rispetto agli utili di Albireo Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2022	n/a	n/a	-US$131m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$6m	US$590k	-US$34m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$136m
Mar 31 2021	n/a	n/a	-US$120m
Dec 31 2020	US$3m	US$570k	-US$108m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$78m
Dec 31 2019	US$3m	US$551k	-US$63m
Sep 30 2019	n/a	n/a	-US$71m
Jun 30 2019	n/a	n/a	-US$63m
Mar 31 2019	n/a	n/a	-US$61m
Dec 31 2018	US$4m	US$530k	-US$46m
Sep 30 2018	n/a	n/a	-US$35m
Jun 30 2018	n/a	n/a	-US$28m
Mar 31 2018	n/a	n/a	-US$19m
Dec 31 2017	US$2m	US$460k	-US$24m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$20m
Dec 31 2016	US$4m	US$400k	-US$16m

Compensazione vs Mercato: La retribuzione totale di Ron ($USD 6.04M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 369.49K ).

Compensazione vs guadagni: La retribuzione di Ron è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Ron Cooper (59 yo)

7.7yrs

Mandato

US$6,041,334

Compensazione

Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ronald H. Cooper	CEO, President & Director	7.7yrs	US$6.04m	0.16% MX$ 26.5m
Simon Nicolas Harford	CFO & Treasurer	4.4yrs	US$1.71m	0.066% MX$ 11.0m
Martha Carter	Chief Regulatory Officer	6.3yrs	US$1.73m	0.018% MX$ 2.9m
Per-Goran Gillberg	Co-Founder & VP of Development	no data	Nessun dato	Nessun dato
Jan Mattsson	Chief Scientific Officer	15.2yrs	US$1.40m	0.17% MX$ 28.4m
Joan Connolly	Chief Technology Officer	1.9yrs	Nessun dato	Nessun dato
Jason Duncan	Chief Legal Officer	4.8yrs	Nessun dato	0.016% MX$ 2.6m
Michelle Graham	Chief Human Resources Officer	3.3yrs	Nessun dato	0.027% MX$ 4.4m
Kristina Torfgard	VP & Global Project Head	no data	Nessun dato	Nessun dato
Pamela Stephenson	Chief Commercial Officer	4yrs	US$1.96m	0.11% MX$ 17.8m
Constantine Chinoporos	Chief Business Officer	1.3yrs	Nessun dato	Nessun dato
Paul Streck	Chief Medical Officer	less than a year	Nessun dato	Nessun dato

4.2yrs

Durata media

58.5yo

Età media

Gestione esperta: Il team dirigenziale di ALBO * è considerato esperto (durata media dell'incarico 4.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ronald H. Cooper	CEO, President & Director	7.5yrs	US$6.04m	0.16% MX$ 26.5m
David Chiswell	Independent Chairman of the Board	15.1yrs	US$282.44k	0.27% MX$ 45.0m
Davey Scoon	Independent Director	6.3yrs	US$266.82k	0.14% MX$ 24.1m
Michael Gutch	Independent Director	7.4yrs	US$264.94k	0.13% MX$ 21.2m
Craig Hopkinson	Director	less than a year	Nessun dato	Nessun dato
Habib Dable	Independent Director	less than a year	Nessun dato	Nessun dato
Stephanie Okey	Independent Director	4.8yrs	US$249.94k	0.14% MX$ 24.0m
Susan Alesina	Director	less than a year	Nessun dato	Nessun dato

5.5yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALBO * sono considerati esperti (durata media dell'incarico 5.5 anni).

Albireo Pharma Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Albireo Pharma, Inc. Announces New Committee Member Appointments

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Insufficient new directors

Recent updates

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases

Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

Albireo Pharma, Inc. to Present Late Breaking Bylvay (odevixibat) Data at AASLD 2022

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® (Odevixibat) in Alagille Syndrome

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of All Types of Progressive Familial Intrahepatic Cholestasis Patients in Italy

Albireo Pharma, Inc. Announces New Committee Member Appointments

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Albireo Pharma, Inc. Announces Lancet Gastroenterology & Hepatology Published the Results of the Pivotal PEDFIC 1 Trial

Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from Russell Microcap Value Index

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Albireo Pharma, Inc. Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Insufficient new directors

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media